PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Wednesday, November 30, 2022: Biosergen AB ("Biosergen" or the "Company") thereby publishes the interim report for the third quarter 2022. The interim report is available as an attached document and on the company website (www.biosergen.net
Summary of the Interim Report for Q3 2022
2022 2021 2022 2021 2021
TSEK July-Sep July-Sep Jan-Sep Jan-Sep Jan-Dec
Other income 493 2.652 3.219 4.653 8.573
Profit/loss -14.515 -6.404 -27.496 -24.202 -34.077
before
depreciation
(EBITDA)
Operating -14.515 -6.404 -27.496 -24.202 -34.077
profit/loss
befor net
financials
Netprofit/los -14.499 -6.550 -27.474 -24.359 -34.318
s for the
period
Earnings per -0,51 -0,40 -0,97 -1,51 -1,22
share (SEK)
- August 26, Biosergen completes the third cohort of BSG005 phase 1 trial
- August 31, Biosergen receives a loan of SEK 7 million to finance continued development
- September 2, Biosergen AB: Biosergen's Board of Directors decides on a rights issue of units of approximately SEK 60.2 million
- September 8, Biosergen moves into the MAD (Multiple Ascending Dose) part of its phase I study after 4 cohorts tested in the SAD (Single Ascending Dose) part of the study
- October 4, Biosergen announces the outcome in the rights issue
The Financial report can be found on our website: https://biosergen.net/investors/filings